Press Release and Publications/

Below you can find more information about our recent Press Releases and Publications

Press Releases

Yahoo Press Release: New Milestones and Upcoming Events for PepVax


July, 2017: PepVax, Inc., an early stage biotechnology company developing an immunotherapy treatment for triple-negative breast cancer (TNBC), today announced several new milestones and upcoming events that demonstrate the company's continued growth...Read more

TEDCO Press Release: Maryland Entrepreneur Resource List Success Story


The Maryland Entrepreneurs Resource List (MERL) started in 2012 and has had some recent success in providing leadership to early stage companies. One example is Ocular Proteomics, LLC, OPL. Joshua Hines, business director for OPL, has contacted several MERL...Read more

Washington Business Journal

Washington Business Journal: Can Indiegogo fund biotech? PepVax bets on it

Biotech and crowdfunding don't sound particularly compatible. The staggering research, clinical and regulatory costs associated with putting "pill number one" on the market seems like it would prevent a Kickstarter or Indiegogo campaign, especially since trading equity for funding isn't legal yet... Read more

Publications

Epitope specificity and protein signaling interactions driving epidemic occurrences of Ebola disease


June, 2015: Paper published by PepVax describing the Epitope specificity and protein signaling interactions driving epidemic occurrences of Ebola disease. Ebolavirus has as main hosts, humans and nonhuman primates where its pathogenic effects result to serious hemorrhagic fever with lethal...Read more

Online Journal of Bioinformatics

A novel strategy of In silico peptide vaccine design for Streptococcus mutans.

August, 2014: Paper published by PepVax describing a novel strategy of In silico peptide vaccine design for Streptococcus mutans. Several attempts have been made towards the development of a viable vaccine for Streptococcus mutans (S. Mutans). This Gram positive bacterium is...Read more